Traders should monitor upcoming mid-2026 clinical readouts for tagmokitug and casdozokitug, which could serve as major catalysts. The improved financial position reduces near-term dilution risk, while LOQTORZI's growth trajectory supports potential revaluation if sales continue accelerating.
Price Chart
Executive Summary
Coherus Oncology reported strong revenue growth for LOQTORZI, with full-year 2025 net revenue reaching $42.2 million, up 60% YoY, driven by increasing patient demand and treatment duration. The company significantly reduced its debt by 90% to $38.8 million and bolstered its cash position to $172.1 million through equity financings, while advancing a promising oncology pipeline with multiple 2026 clinical readouts expected.
Key Financial Metrics
Key Facts
- LOQTORZI net revenue grew 60% YoY to $42.2 million in 2025, up from $26.4 million in 2024
- Q4 2025 LOQTORZI revenue was $12.4 million, up 64% YoY and 11% QoQ
- Debt reduced from $480 million peak to $38.8 million by end of 2025
- Cash, cash equivalents, and marketable securities totaled $172.1 million as of December 31, 2025
- Company raised $54.9 million in gross proceeds from two equity offerings in late 2025 and early 2026
- Net loss from continuing operations narrowed to $183.1 million in 2025 from $215.4 million in 2024
- Phase 2 data for casdozokitug in uHCC showed 38% ORR and 17% CR rate; multiple 2026 clinical readouts expected
Financial Impact
Revenue increased by $15.8 million YoY; net loss improved by $32.3 million; cash position increased by $46.1 million despite operating losses
Risk Factors
- High cash burn: $138.5 million used in operating activities in 2025
- Significant dilution from recent equity raises: ~33 million new shares issued in 2025-2026
- Pipeline remains early-stage with no guarantees of clinical success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252311 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Press Release | $1.34 $1.29 | ▼ −4.10% | ▼ −3.11% | $1.16 (−13.43%) |
Jul 22, 2026 10w ago | Press Release | $1.43 $1.33 | ▼ −6.99% | ▼ −9.89% | $1.16 (−18.88%) |
Jun 15, 2026 15w ago | 8-K | $1.38 $1.45 | ▲ +5.07% | ▲ +4.87% | $1.16 (−15.94%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.40 $1.54 | ▼ −10.00% | ▼ −8.22% | $1.16 (+17.14%) |
May 28, 2026 18w ago | DEFA14A | $1.65 $1.50 | ▼ −9.09% | ▼ −5.95% | $1.16 (−29.70%) |
May 11, 2026 20w ago | Press Release | $1.71 $1.36 | ▼ −20.47% | ▼ −18.74% | $1.16 (−32.16%) |
May 5, 2026 21w ago | DEFA14A | $1.75 $1.47 | ▼ −16.00% | ▼ −18.78% | $1.16 (−33.71%) |
May 4, 2026 21w ago | Press Release | $1.73 $1.57 | ▼ −9.25% | ▼ −14.89% | $1.16 (−32.95%) |
Mar 9, 2026 29w ago | Press Release | $1.95 $1.70 | ▼ −12.82% | ▼ −12.67% | $1.16 (−40.51%) |
Mar 2, 2026 30w ago | Press Release | $1.65 $1.60 | ▼ −3.03% | ▲ +4.91% | $1.16 (−29.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access